FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending September 18, 2008
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Quest Diagnostics Inc - Variable Sales Forward Agreements
GlaxoSmithKline plc (GSK) today confirmed that the Variable Sales Forward Agreements (VSF Agreements) with Lehman Brothers Finance S.A., with respect to a total of 20 million shares of common stock of Quest Diagnostics Inc., have terminated with no material financial impact to GSK expected. GSK has requested that the shares, which were pledged under the VSF Agreements and held in custody by Lehman Brothers Inc, be returned to GSK.
Simon Bicknell
Company Secretary
18 September 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorised.
GlaxoSmithKline plc
(Registrant)
Date: September 18, 2008
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc